Dianthus Therapeutics, Inc. /DE/ — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Dianthus Therapeutics reported Q2 2026 net loss of $50.2M ($0.90/share) vs. $31.6M ($0.88/share) YoY, with R&D expenses rising 85% to $48.7M and G&A up 53% to $13.6M, driven by Phase 3 EMERGE initiation in gMG and expanded headcount. The company holds ~$1.2B cash/investments (as of June 30, 2026), projected to fund operations into 2030. Key pipeline milestones: Phase 3 CAPTIVATE (CIDP) achieved 75% response rate in interim analysis of 40 patients (vs. 50% target); Phase 2 MoMeNtum (MMN) enrollment exceeded target at 46 patients with results expected December 2026; DNTH212 (rheumatology) Phase 1 data expected year-end 2026; DNTH312 (novel bifunctional) targeting Phase 1 readiness by end 2027.
Why this rating
Pipeline progress is encouraging but clinical-stage; $1.2B cash is substantial (200% of market cap), reducing near-term financing risk. Burn acceleration and lack of revenue offset positive trial data. Moderate for early-stage biotech.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.